Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Antimicrob Agents ; 28(5): 472-6, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17046209

RESUMO

A national multicentre prevalence study was undertaken to determine the bacterial strains associated with mild-to-moderate acute exacerbations of chronic bronchitis (AECB) in the primary care setting and the susceptibility of isolated pathogens to different antimicrobials usually prescribed to these patients. All samples were processed by a central reference laboratory. Microdilution tests were carried out to establish the minimum inhibitory concentration (MIC) of various antimicrobials. A double-disk test was performed to establish the macrolide resistance phenotype in Streptococcus pneumoniae. Tests to detect the presence of beta-lactamase in Haemophilus influenzae and Moraxella catarrhalis and polymerase chain reaction to detect the presence of ermB and mefA genes in S. pneumoniae isolates were also performed. A total of 1537 patients were included in the trial and 468 microorganisms were isolated from sputum samples, with the most frequent isolates being S. pneumoniae (34.8%), M. catarrhalis (23.9%) and H. influenzae (12.6%). Resistance rates of pneumococci were 47.2% for penicillin, 1.2% for amoxicillin, 34.3% for macrolides (87.5% of which showed high-level resistance), 13.6% for cefuroxime/axetil and 4.2% for levofloxacin. No bacterial isolates showed resistance to telithromycin. Empirical antibiotic treatment was prescribed to 98.3% of patients, including macrolides to 36.6%, amoxicillin with or without clavulanic acid to 32.3% and fluoroquinolones to 16.1%. In conclusion, S. pneumoniae was the most frequently isolated bacteria in patients with mild-to-moderate AECB. Despite the high rates of resistance of pneumococci to macrolides, they continue to be the most widely used antibiotics in primary care to treat AECB.


Assuntos
Antibacterianos/uso terapêutico , Bronquite Crônica/tratamento farmacológico , Farmacorresistência Bacteriana/genética , Escarro/microbiologia , Adulto , Idoso , Antibacterianos/farmacologia , Proteínas de Bactérias/genética , Bronquite Crônica/epidemiologia , Bronquite Crônica/microbiologia , Estudos Transversais , Feminino , Haemophilus influenzae/efeitos dos fármacos , Haemophilus influenzae/genética , Haemophilus influenzae/isolamento & purificação , Humanos , Masculino , Proteínas de Membrana/genética , Metiltransferases/genética , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Moraxella catarrhalis/efeitos dos fármacos , Moraxella catarrhalis/genética , Moraxella catarrhalis/isolamento & purificação , Prevalência , Atenção Primária à Saúde/estatística & dados numéricos , Espanha/epidemiologia , Streptococcus pneumoniae/efeitos dos fármacos , Streptococcus pneumoniae/genética , Streptococcus pneumoniae/isolamento & purificação
2.
Rev Clin Esp ; 190(3): 134-6, 1992 Feb.
Artigo em Espanhol | MEDLINE | ID: mdl-1561456

RESUMO

We present two cases of visceral leishmaniasis in patients with AIDS which represent two different clinical patterns of the disease. Special emphasis is made on the need to lavish bone marrow studies in those patients with AIDS who present fever of unknown origin since immunodepression can modify the classical clinical picture of the disease. According to our experience, visceral leishmaniasis should be included amongst the infections indicative of AIDS in patients with HIV infection.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Leishmaniose Visceral/diagnóstico , Adulto , Antimônio/uso terapêutico , Exame de Medula Óssea , Feminino , Febre de Causa Desconhecida/diagnóstico , Humanos , Leishmaniose Visceral/tratamento farmacológico , Leishmaniose Visceral/etiologia , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...